Back

Alpha-Lipoic Acid

Reducing symptoms of diabetic neuropathy

Evidence · Grade DSafety · Generally safe
Meta-analysis availableHuman trial evidenceTraditional useInteraction riskNeeds more research

A potent antioxidant studied for diabetic neuropathy and insulin sensitivity.

Alpha-lipoic acid (ALA) is a sulfur-containing fatty acid that functions as both a water- and fat-soluble antioxidant. Well-studied for diabetic peripheral neuropathy.

Quick answer

Evidence Summary

Evidence · Grade D

The B evidence grade is supported by a number of human clinical trials, including randomized controlled trials and meta-analyses, particularly for its studied applications in nerve health and blood sugar management. While evidence suggests benefits in certain areas, the overall strength and consistency across all potential applications vary.

Last reviewed · Jun 2026

Have you tried Alpha-Lipoic Acid?

Vote in 5 seconds. Add details if you want.

Your experience for Multiple Sclerosis (MS):

Commonly Combined With

Other remedies frequently used alongside this one — from curated relationships, community reports, and shared protocols.

Community signal breakdown

Where this remedy is being discussed across the web and community.

People Like Me insights

As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.

Community Discussions

What people say about Alpha-Lipoic Acid

Search on Reddit →

Latest News

Latest news on Alpha-Lipoic Acid

More on Google News →

Health Videos

Health videos on Alpha-Lipoic Acid

More on YouTube

Why It Works

Regenerates other antioxidants, improves insulin-mediated glucose uptake, and reduces oxidative stress in nerves.

How it works in more detail

Alpha-lipoic acid (ALA) functions as a cofactor for mitochondrial enzymes involved in energy metabolism. It appears to possess antioxidant properties, directly scavenging reactive oxygen species and regenerating other antioxidants like vitamins C and E, and glutathione. ALA also appears to modulate inflammatory pathways, potentially by inhibiting NF-κB activation. In some contexts, it may improve insulin sensitivity by facilitating glucose uptake in certain cells. Research regarding these mechanisms is ongoing and includes both preclinical and human studies.

How to use

Always consult a qualified clinician.

Editorial guidance

Suggested dosage
300–600 mg/day on empty stomach
Research dosage range
300–1800 mg/day
Typical onset
Effects of alpha-lipoic acid may not be immediate; consistent daily use over several weeks or months is typically reported in studies before potential benefits, such as improvements in nerve comfort or blood sugar parameters, are observed.
Typical forms
capsule, tablet
Quality markers
When selecting an alpha-lipoic acid supplement, look for products that specify the form (e.g., R-lipoic acid, racemic ALA). Third-party testing for purity and potency can help ensure the product meets label claims and is free from contaminants. Reputable manufacturers often provide certificates of analysis.
Medication interactions
  • Antidiabetic drugs (may enhance blood sugar lowering effects)
  • Thyroid hormones (may reduce efficacy)
  • Chemotherapy drugs (potential interactions, consult oncologist)
  • Anticoagulants (potential for increased bleeding risk, theoretical)
Avoid if
  • Hypoglycemia (without medical supervision)
  • Thyroid disorders (without medical supervision)
  • Known allergy to alpha-lipoic acid

Community tips

No community tips yet — be the first to share what worked for you.

Suggested dosage

300–600 mg/day on empty stomach

General guidance — discuss specifics with a clinician.

Active medicinal compounds

Alpha-lipoic acid (ALA), specifically the R-lipoic acid isomer, which is the biologically active form.

Traditional use

Alpha-lipoic acid itself is not a traditional herbal remedy. It is a compound naturally occurring in the body and certain foods, identified relatively recently and primarily studied in modern biochemical and pharmacological contexts.

Safety

Safety warnings

May lower blood sugar — monitor if on diabetes medication. Can deplete biotin with long-term use.

Avoid if

  • Hypoglycemia (without medical supervision)
  • Thyroid disorders (without medical supervision)
  • Known allergy to alpha-lipoic acid

Medication interactions

  • Antidiabetic drugs (may enhance blood sugar lowering effects)
  • Thyroid hormones (may reduce efficacy)
  • Chemotherapy drugs (potential interactions, consult oncologist)
  • Anticoagulants (potential for increased bleeding risk, theoretical)

Reported side effects

  • Nausea
  • Stomach upset
  • Diarrhea
  • Skin rash
  • Dizziness

General guidance — discuss specifics with a clinician.

Evidence ecosystem

Scientific literature, clinical guidance, government sources, ongoing research, traditional use, and lived experience — grouped by source type and quality.

Overall grade (D)

The B evidence grade is supported by a number of human clinical trials, including randomized controlled trials and meta-analyses, particularly for its studied applications in nerve health and blood sugar management. While evidence suggests benefits in certain areas, the overall strength and consistency across all potential applications vary.

Filter by source type

Meta-Analyses(1)

Pooled analyses across multiple human trials.

Very High Quality
  • The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.

    Akbari M, Ostadmohammadi V, Tabrizi R, Mobini M, Lankarani KB, Moosazadeh M · Nutrition & metabolism · 2018

    This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to determine the effect of alpha-lipoic acid (ALA) supplementation on the inflammatory markers among patients with metabolic syndrome (MetS) and related disorders. We searched the following databases until November 2017: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran's Q test and I-square (I2) statistic. Data were pooled by using the random-effect model and standardized mean difference (SMD) was considered as the summary effect size. Eighteen trials out of 912 potential citations were found to be eligible for our meta-analysis. The findings indicated that ALA supplementation significantly decreased C-reactive protein (CRP) (SMD = - 1.52; 95% CI,

    Meta-AnalysisPubMedVery High Quality

Observational Studies(6)

Cohort, case-control, and cross-sectional human studies.

Moderate Quality
  • Alpha-Lipoic Acid.

    Nguyen H, Pellegrini MV, Gupta V · 2026

    Observational StudyPubMedLow Quality
  • Effects of alpha lipoic acid on metabolic syndrome: A comprehensive review.

    Najafi N, Mehri S, Ghasemzadeh Rahbardar M, Hosseinzadeh H · Phytotherapy research : PTR · 2022

    Metabolic syndrome (MetS) is a multifactorial disease with medical conditions such as hypertension, diabetes, obesity, dyslipidemia, and insulin resistance. Alpha-lipoic acid (α-LA) possesses various pharmacological effects, including antidiabetic, antiobesity, hypotensive, and hypolipidemia actions. It exhibits reactive oxygen species scavenger properties against oxidation and age-related inflammation and refines MetS components. Also, α-LA activates the 5' adenosine monophosphate-activated protein kinase and inhibits the NFκb. It can decrease cholesterol biosynthesis, fatty acid β-oxidation, and vascular stiffness. α-LA decreases lipogenesis, cholesterol biosynthesis, low-density lipoprotein and very low-density lipoprotein levels, and atherosclerosis. Moreover, α-LA increases insulin secretion, glucose transport, and insulin sensitivity. These changes occur via PI3K/Akt activation. On the other hand, α-LA treats central obesity by increasing

    Observational StudyPubMedLow Quality
  • Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features.

    Capece U, Moffa S, Improta I, Di Giuseppe G, Nista EC, Cefalo CMA · Nutrients · 2022

    Alpha-lipoic acid (ALA) is a natural compound with antioxidant and pro-oxidant properties which has effects on the regulation of insulin sensitivity and insulin secretion. ALA is widely prescribed in patients with diabetic polyneuropathy due to its positive effects on nerve conduction and alleviation of symptoms. It is, moreover, also prescribed in other insulin resistance conditions such as metabolic syndrome (SM), polycystic ovary syndrome (PCOS) and obesity. However, several cases of Insulin Autoimmune Syndrome (IAS) have been reported in subjects taking ALA. The aim of the present review is to describe the main chemical and biological functions of ALA in glucose metabolism, focusing on its antioxidant activity, its role in modulating insulin sensitivity and secretion and in symptomatic peripheral diabetic polyneuropathy. We also provide a potential explanation for increased risk for the development of IAS. Alpha-lipoic acid (ALA) is a supplement for managing chronic diseases

    Observational StudyPubMedLow Quality

Animal Studies(1)

Preclinical animal research — not a substitute for human evidence.

Low Quality
  • Effects of alpha-lipoic acid on chemerin secretion in 3T3-L1 and human adipocytes.

    Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, López-Yoldi M, Sinal CJ, Martínez JA · Biochimica et biophysica acta · 2016

    Chemerin is a novel adipokine associated with obesity and insulin resistance. α-Lipoic acid (α-LA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of α-LA on chemerin production in adipocytes in absence or presence of TNF-α, insulin and AICAR. The potential signaling pathways involved in α-LA effects on chemerin were also analyzed. α-LA actions on chemerin were tested in differentiated 3T3-L1 adipocytes and in some cases in human subcutaneous and omental adipocytes. Chemerin mRNA levels were measured by RT-PCR and the amount of chemerin secreted to culture media was determined by ELISA. α-LA induced a concentration-dependent inhibition on both chemerin secretion and mRNA levels in 3T3-L1 adipocytes. The AMPK activator AICAR and the PI3K inhibitor LY294002 dramatically abrogated both chemerin secretion and gene expression, and further potentiated the inhibitory effect of α-LA on che

    Animal StudyPubMedLow Quality

Clinical Trial Registries(3)

Registered ongoing or completed trials (ClinicalTrials.gov).

Moderate Quality
  • Effect of Supplementation With Alpha-lipoic Acid and Silybum Marianum (LUDLEV®) in Association With a Mediterranean Diet for the Improvement of Metabolic Dysfunction-associated Fatty Liver Disease

    n=50 · NCT05913986 · UNKNOWN · UNKNOWN

    This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.

    Clinical TrialClinicalTrials.govModerate Quality
  • Effect of Alpha-Lipoic Acid Supplementation on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females Treated With Letrozole

    n=150 · NCT06418347 · UNKNOWN · UNKNOWN

    This research study aims to investigate the effect of adding Alpha lipoic acid (ALA) supplement to letrozole treatment in infertile women with polycystic ovary syndrome (PCOS). The study will include 150 PCOS participants seeking fertility treatment. They will be randomly divided into two groups - control and intervention. Both groups will receive standard PCOS care including lifestyle counseling. The control group will be treated with letrozole only. The dose will start at (2.5 mg) for 5 days and can increase up to (7.5 mg) based on response. The intervention group will take ALA supplements along with letrozole treatment. ALA tablets (600mg) will be given three times daily starting from day 3 of the menstrual cycle till human chorionic gonadotropin (HCG) injection day. Letrozole dose for the intervention group will also follow the same incremental protocol as the control group. Patient monitoring will involve trans-vaginal ultrasound scans on certain cycle days to check follicle growth and the thickness of uterus lining. Once a follicle reaches 18mm in size, an intramuscular HCG injection will be given. Couples will be asked to have intercourse 36 hours after the injection. Pregnancy will be tested two weeks later if menstruation does not occur. Metabolic, hormonal, and ultrasound parameters will be recorded at baseline and follow-ups. All adverse effects of the treatment will be noted. The study period will be a maximum of 3 treatment cycles or untill pregnancy is achieved. Outcome measures include ovulation and pregnancy rates. The effect of ALA on metabolic parameters (fasting glucose, fasting insulin, BMI and HOMA-IR), hormone levels (mid-luteal progesterone and serum estradiol), and follicular growth will also be assessed. Proper sample size and randomization methods will be followed. A Statistical analysis of collected data will help determine if ALA has additional benefits when combined with letrozole for PCOS fertility treatment. Finally, the results will be statistically analyzed. Statistical analysis will be done using the SPSS statistical software package.

    Clinical TrialClinicalTrials.govModerate Quality
  • Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients

    n=150 · NCT07182526 · RECRUITING · RECRUITING

    This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.

    Clinical TrialClinicalTrials.govModerate Quality

Limitations: Many human studies, even randomized controlled trials, are often relatively small in sample size. There can be heterogeneity in study designs, populations, dosages, and duration of intervention, making direct comparisons and synthesis challenging. Further large-scale, long-term trials are often needed to confirm and generalize findings.

This page is educational. Statements use phrases like "may support" and "has been studied for"because no remedy here is approved to cure, treat, or reverse any condition. Discussion happens on the ailment pages — community statistics here are derived from those reports. Always consult a qualified clinician.

Tried Alpha-Lipoic Acid?

Help others see what actually works.